Europe needs a single, deep capital market.
作者信息
Hodgson John
出版信息
Nat Biotechnol. 2002 Oct;20(10):960-1. doi: 10.1038/nbt1002-960b.
PMID:12355101
Abstract
摘要
相似文献
1
Europe needs a single, deep capital market.
Nat Biotechnol. 2002 Oct;20(10):960-1. doi: 10.1038/nbt1002-960b.
2
Companies struggle amid stock market gloom.
Nat Biotechnol. 2002 Oct;20(10):961-2. doi: 10.1038/nbt1002-961.
3
Biotechs await single European financial market.
Nat Biotechnol. 2003 Dec;21(12):1417. doi: 10.1038/nbt1203-1417a.
4
Public markets show signs of life.
Nat Biotechnol. 2003 Aug;21(8):833-4. doi: 10.1038/nbt0803-833.
5
Where the money is.
Nat Biotechnol. 2006 Mar;24(3):240-2. doi: 10.1038/nbt0306-240.
6
Diversa restructures, raising question over bioprospecting.
Nat Biotechnol. 2006 Mar;24(3):229. doi: 10.1038/nbt0306-229.
7
Crystal gazing: biotech's financial outlook: the biotech analyst's view.
Nat Biotechnol. 2006 Mar;24(3):261-2. doi: 10.1038/nbt0306-261a.
8
European markets target foreign biotechs.
Nat Biotechnol. 2003 Jul;21(7):719. doi: 10.1038/nbt0703-719.
9
The rise of European venture capital for biotechnology.
Nat Biotechnol. 2003 Nov;21(11):1287-91. doi: 10.1038/nbt1103-1287.
10
Financing biotechnology in an inefficient market.
Nat Biotechnol. 1999 Feb;17 Suppl:BE31-2. doi: 10.1038/4640.
Zotero 插件